Hua Chang
Karyopharm Therapeutics (United States)(US)
Publications by Year
Research Areas
Cancer, Lipids, and Metabolism, Nuclear Structure and Function, Prostate Cancer Treatment and Research, Cancer-related Molecular Pathways, Protein Degradation and Inhibitors
Most-Cited Works
- → Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma(2019)662 cited
- → A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma(2021)66 cited
- → Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial(2022)40 cited
- → Combined Targeting of Estrogen Receptor Alpha and XPO1 Prevent Akt Activation, Remodel Metabolic Pathways and Induce Autophagy to Overcome Tamoxifen Resistance(2019)20 cited
- → Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status(2021)18 cited
- → Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression(2018)16 cited
- → Selinexor inhibits growth of patient derived chordomas in vivo as a single agent and in combination with abemaciclib through diverse mechanisms(2022)8 cited
- → Molecular predictors of response to selinexor in advanced unresectable de-differentiated liposarcoma (DDLS).(2021)3 cited
- → Pathogenicity Analysis of Klebsiella oxytoca Isolated from Larus ridibundus Migratory Birds(2018)2 cited
- → A Six-Protein Activity Signature Defines Favorable Response to Selinexor Treatment for Patients with Diffuse Large B-Cell Lymphoma (DLBCL)(2020)1 cited